View the WOC 2022 symposium on "Expert clinical insights: Targeting the Ang/Tie2 pathway for the management of retinal diseases"

Targeting additional pathways beyond vascular endothelial growth factor A (VEGF-A) may address treatment challenges in retinal diseases such as neovascular age-related degeneration (nAMD) and diabetic macular edema (DME) and optimise patient outcomes. The Ang/Tie2 pathway drives vascular instability in these pathological conditions, and targeting this pathway may provide opportunities for further thearapeutic adavancements. In this symposium, 5 experts summarise the impact of dual Ang-2/VEGF-A inhibition, explore therapeutic advancements targeting the Ang/Tie2 pathway and review the latest clinical data for dual Ang-2/VEGF-A inhibition in nAMD and DME. The session also includes the presentation and discussion of real-world experiences of dual Ang-2/VEGF-A inhibition in nAMD and DME. This content is intended for HCPs who have attended the symposium.